<DOC>
	<DOCNO>NCT00704483</DOCNO>
	<brief_summary>This study evaluate efficacy SBR759 compare sevelamer HCl lower serum phosphate level Chronic Kidney Disease patient hemodialysis</brief_summary>
	<brief_title>Efficacy SBR759 Lowering Serum Phosphate Levels Chronic Kidney Disease Patients Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Inclusion criterion Men woman least 18 year old . Stable maintenance renal replacement therapy 3 time per week . Controlled Serum phosphate phosphatebinder therapy . Serum phosphate level ≥ 6.0 mg/dL ( &gt; 1.9 mmol/L ) prior study treatment initiation . Exclusion criterion Peritoneal dialysis . Parathyroidectomy transplant schedule study . Uncontrolled hyperparathyroidism History hemochromatosis ferritin &gt; 1000 µg/L . Clinically significant GI disorder Unstable medical condition Chronic Kidney Disease . Treated oral iron . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>hyperphosphatemia</keyword>
	<keyword>hemodiafiltration</keyword>
</DOC>